Tongkat ali and Fadogia agrestis are frequently combined in commercial formulas, but their research foundations are entirely different. When we put these two herbs side by side, only one of them has a row to fill in.
Tongkat ali possesses human clinical trials, a recognized chemical marker standard, and detailed safety evaluations by major regulatory agencies. Fadogia agrestis has zero human trials, zero study registrations on ClinicalTrials.gov, and no established quality specifications. The entire evidence base for Fadogia agrestis rests on short-term rodent studies where identical intake levels caused endocrine shifts alongside cellular damage in testicular tissue.
The Verdict
Tongkat ali vs Fadogia agrestis
| Attribute | Tongkat ali | Fadogia agrestis |
|---|---|---|
| Human clinical trials | Five pooled randomised trials in Medicina | Zero published clinical trials in humans |
| Study registrations | Six trials listed on ClinicalTrials.gov | Zero studies listed on ClinicalTrials.gov |
| Total trial participants | 267 total participants across pooled trials | Zero human participants studied |
| Effect on serum testosterone | Standardised mean difference of 1.352 overall | Unmeasured in human trials |
| Statistical heterogeneity and bias | Heterogeneity of 87.27% with significant publication bias | Not applicable given the absence of clinical trials |
| Chemical marker standard | Standardised to 0.8% to 1.5% eurycomanone | No established marker compound specification |
| Market product authenticity | Testing shows variable marker content and adulteration | Analytical testing found target compounds absent in 5 of 17 brands |
| Safety and toxicological documentation | Evaluated in a dedicated LiverTox chapter | Rodent trials show testicular and organ enzyme leakage |
| European regulatory classification | Novel food application rejected by EFSA due to genotoxicity | Classified as an unauthorised novel food in the EU |
The Disparity In Published Research
Tongkat ali and Fadogia agrestis possess fundamentally unequal volumes of clinical investigation. The Leisegang meta-analysis found nine human studies of Eurycoma longifolia and could pool five of them; a PubMed search of the whole Fadogia genus returns twenty citations and no human trial.
A systematic review by Leisegang and colleagues in Medicina identified nine human studies evaluating Eurycoma longifolia as an isolated intervention. Only five of those studies met criteria for statistical pooling. Those five trials comprised 267 total participants across treatment and control arms. The pooled effect yielded a standardised mean difference of 1.352 for serum total testosterone. Men with baseline levels under 300 ng/dL exhibited a larger pooled increase of 1.861.
However, human research on Fadogia agrestis does not exist. A search on PubMed reveals twenty total citations across the entire genus. Zero records represent human clinical trials. A 2024 review in the International Journal of Impotence Research evaluated 27 proposed testosterone ingredients across 52 human studies. The authors rated tongkat ali as only possibly effective. The review omitted Fadogia agrestis completely because no human data met review standards. In a 2023 rodent study published in Reproductive Sciences, Ogunro and Yakubu concluded that clinical trials in humans remain necessary before recommending the herb. For readers evaluating TRT vs testosterone boosters, the difference between these two botanicals is a division between limited clinical data and zero human testing.
Methodological Limitations In Tongkat Ali Studies
Published human trials for tongkat ali contain high statistical heterogeneity alongside evidence of publication bias. The meta-analysis by Leisegang reported an I-squared heterogeneity of 87.27%. Individual study results diverged sharply from one another. Begg's test for publication bias was statistically significant with a p-value of 0.0243. This statistical signal suggests that small negative trials were withheld from academic publication. Study quality was also uneven. Risk-of-bias tools flagged two trials at low risk and one at high risk. Sample sizes remained modest. Individual randomised trials enrolled only 32, 37, 39, 40, and 140 participants.
In addition, commercial concentration shapes the research base. Seven of the nine reviewed studies evaluated a single proprietary extract from one manufacturer. Authorship ties appear frequently throughout this trial programme. For example, the 2021 trial by Chinnappan and colleagues in Food & Nutrition Research enrolled 105 men aged 50 to 70 years. Employees of the extract manufacturer authored the study. Other publications within the programme carry similar corporate competing-interest disclosures (competing interest report). That 12-week trial found an increase in total testosterone, but recorded no significant between-group difference in free testosterone and no change in SHBG.
Other studies had design limitations. A 6-month trial by Leitão and colleagues in Maturitas lacked an arm receiving the herb without concurrent exercise. An earlier trial by Ismail et al. in 109 men did not evaluate serum testosterone as a primary endpoint. A frequently cited paper by Tambi et al. was an uncontrolled open-label case series without a placebo group. Furthermore, the widely advertised thirty-seven percent testosterone increase from Talbott et al. 2013 measured salivary hormone concentrations rather than blood serum. Salivary readings do not mirror serum values. A 4-week trial in 33 trained adults (2024 trial in 33 adults) found no differences in salivary free testosterone, cortisol, or body composition. These laboratory discrepancies matter when interpreting signs of low testosterone and evaluating free vs total testosterone measurements.
Identical Dosages For Efficacy And Toxicity In Fadogia Research
Animal studies of Fadogia agrestis document endocrine increases and tissue damage at the exact same oral intake levels. The commercial reputation of the herb stems from a 2005 rodent study by Yakubu, Akanji, and Oladiji in the Asian Journal of Andrology. Male albino rats received aqueous stem extract at 18, 50, and 100 mg/kg daily for five days. The researchers noted increases in mounting frequency alongside higher serum testosterone. The paper lasted only five days. It published no absolute numeric values for testosterone in the abstract.
Three years later, the same three investigators published a 28-day toxicity evaluation in the Journal of Ethnopharmacology. They administered the identical doses of 18, 50, and 100 mg/kg daily. Every dose produced significant disruptions in testicular biochemistry. The extract increased testicular cholesterol, glycogen, sialic acid, and gamma-glutamyl transferase. Concurrently, testicular alkaline phosphatase, acid phosphatase, glutamate dehydrogenase, and total protein concentrations fell significantly. The authors concluded these alterations indicate adverse effects on male rat testicular function. A 10-day recovery window restored only select markers, primarily at the lowest dose of 18 mg/kg. The authors noted this recovery suggests absence of permanent toxicity at 18 mg/kg, leaving higher doses unresolved.
In 2009, the same laboratory published a third 28-day study in Human & Experimental Toxicology. At 18, 50, and 100 mg/kg, enzymes leaked from liver and kidney tissue into the bloodstream. Serum malondialdehyde rose across all treated groups, pointing to plasma membrane disruption via lipid peroxidation. Although animals survived without gross organ swelling, cellular indices shifted unfavourably.
Translating Rodent Toxicology To Human Biology
Rodent milligram per kilogram amounts cannot be translated directly to human body weight without adjusting for body surface area. Lay commentators often multiply animal quantities by human kilograms. Regulatory agencies reject that approach.
Guidance published by the Food and Drug Administration explains how to calculate initial safe human doses from animal toxicity studies. The conversion relies on body surface area rather than simple body mass. As detailed by Nair and Jacob, each species has a specific Km conversion factor. The rat Km value is 6. The human Km value is 37. Dividing the rat factor by the human factor yields a conversion divisor of approximately 6.2. A rat mg/kg figure overstates the equivalent human value roughly sixfold before any other safety buffer is introduced.
Once a human equivalent dose is derived, regulators apply a standard safety factor of 10. This adjustment sets an upper boundary for initial human clinical testing. It is never a consumption target. The Fadogia agrestis rodent doses of 18, 50, and 100 mg/kg represent animal toxicology data. Treating those amounts as human guidelines ignores standard pharmacokinetics.
Quality Control And Analytical Testing In Commercial Bottles
Independent chemical analyses reveal that commercial formulations for both botanicals frequently fail to deliver the compounds listed on their labels. Tongkat ali products have an established chemical benchmark. The Malaysian standard specifies an extract containing 0.8% to 1.5% eurycomanone as the primary active marker. Retail products do not meet that benchmark.
In a study published in Fitoterapia, Mutschlechner and colleagues tested eight commercial Eurycoma longifolia products using validated high-performance liquid chromatography. Three of the eight products contained no detectable tongkat ali compounds whatsoever. In the five products with active material, eurycomanone content ranged from 0.22 mg to 1.84 mg per capsule. That represents an eightfold variation between competing brands. Botanical authentication faces equal hurdles. Research in Pharmaceutical Biology by Abubakar and colleagues examined retail supplements using DNA barcoding. Only 37% of tested products were authentic, while 27% were adulterated with substitute botanicals. Furthermore, chemical screening in Food Chemistry identified undeclared sildenafil analogues in two internet-purchased tongkat ali supplements. Heavy metal contamination is also documented. Testing of 100 preparations by Ang et al. 2004 found 36% exceeded the 0.5 parts per million mercury limit. A 2006 follow-up analysis (Ang & Lee 2006) found 26% of products exceeded safe mercury thresholds.
Fadogia agrestis demonstrates even steeper quality deficits. The species lacks an accepted marker compound standard. Scientists at the University of Mississippi's National Center for Natural Products Research evaluated 17 commercial Fadogia supplements in Planta Medica. Five of the seventeen products contained no detectable target phenolics at all. Across the remaining twelve products, phenolic content varied ninefold, from 0.3 to 2.7 mg per daily serving. Separately, veterinary literature warns that a related plant in the same genus, Fadogia homblei, causes fatal heart failure known as gousiekte in ruminants. That toxicity belongs to a distinct species and does not represent evidence regarding Fadogia agrestis, but it underscores the general lack of phytochemical characterisation across the genus.
Toxicological Findings And Regulatory Oversight
United States law permits the retail sale of dietary supplements without premarket proof of efficacy or safety. Under 21 U.S.C. §321(ff), supplements are regulated as foods rather than pharmaceutical drugs. Under 21 U.S.C. §342(f)(1), enacted under the Dietary Supplement Health and Education Act (DSHEA), the federal government carries the legal burden of demonstrating harm to remove a product. Manufacturers must submit safety notifications for new dietary ingredients under 21 U.S.C. §350b(a) at least 75 days before distribution. The Federal Trade Commission requires competent and reliable scientific evidence for health advertising. However, no enforcement action naming either herb has been confirmed.
Overseas authorities enforce stricter thresholds. EFSA assessed Eurycoma longifolia root extract as a novel food in 2021. EFSA concluded safety was not established under any condition of use. The rejection arose from genotoxicity concerns, including a positive in vitro chromosome aberration test and a positive in vivo comet assay in gastrointestinal tissue at 2,000 mg/kg. This assessment did not evaluate testosterone outcomes. Genotoxicity findings remain contested. A 2013 rodent study by Li et al. 2013 reported no genotoxicity with powdered whole root, contrasting with the concentrated extract evaluated by European regulators.
In the United States, the National Institute of Diabetes and Digestive and Kidney Diseases maintains a chapter on tongkat ali in its LiverTox database. LiverTox documents cases of clinically apparent liver injury in bodybuilders. A 2024 case report in Cureus detailed acute hepatocellular injury in a 47-year-old male following one week of use. Nevertheless, LiverTox notes that undisclosed anabolic steroid use among bodybuilders weakens direct causality. For Fadogia agrestis, the European Commission classifies the botanical as an unauthorised novel food in the Novel Food Catalogue due to insufficient evidence of human consumption before May 1997. The herb cannot be lawfully sold in European Union member states without premarket safety authorization.
Clinical Realities Of Modifying Testosterone Within Normal Ranges
Raising serum testosterone within the normal physiological range produces modest clinical changes even when achieved using pharmaceutical hormone replacement. The Endocrine Society clinical practice guideline advises diagnosing hypogonadism only in men with persistent symptoms and unequivocally low blood concentrations. The Testosterone Trials to examine 790 men aged 65 and older with baseline testosterone below 275 ng/dL. Restoring hormones to normal ranges improved sexual desire and mood. However, treatment produced no significant improvement in walking distance or vitality.
The subsequent TRAVERSE trial enrolled men with fasting levels below 300 ng/dL to establish cardiovascular safety parameters. Pharmaceutical therapies show minimal benefits for men who already fall inside healthy reference intervals. Botanical supplements that claim to nudge levels within normal parameters lack data showing measurable functional gains. Readers can explore our evaluations of does zinc increase testosterone and how to test biomarkers with a men's hormone panel. In addition, reviewing normal vs optimal ranges and the symptoms of male menopause provides realistic perspective on endocrine health.
Frequently Asked Questions
Does Fadogia agrestis have any human studies?
No. A complete search of PubMed and ClinicalTrials.gov reveals zero human trials, zero clinical safety studies, and zero trial registrations for Fadogia agrestis. Every circulating claim regarding its efficacy traces back to rodent experiments conducted between 2005 and 2009. The researchers who authored those animal studies explicitly concluded in 2023 that human clinical trials remain necessary before anyone can recommend the extract.
Does tongkat ali actually raise testosterone?
The evidence is mixed and limited by significant methodological weaknesses. A 2022 meta-analysis of five pooled randomised controlled trials found an increase in total serum testosterone, with a standardised mean difference of 1.352 overall and 1.861 in men starting below 300 ng/dL. However, the trial data showed 87.27% statistical heterogeneity, significant publication bias, and heavy commercial concentration, with seven of nine studies testing one proprietary extract. In addition, trials frequently failed to demonstrate increases in free testosterone or functional strength.
Is Fadogia agrestis safe?
Its safety in humans is unestablished. In animal research, the same 18, 50, and 100 mg/kg doses that produced hormonal shifts over five days caused significant testicular damage over 28 days. The authors observed increased testicular weight ratios, altered enzyme concentrations, and decreased testicular protein levels. Follow-up studies also recorded cellular enzyme leakage in liver and kidney tissues. In the European Union, regulators classify the herb as an unauthorised novel food due to a lack of documented human consumption.
Why do supplements stack tongkat ali and Fadogia agrestis together?
Commercial manufacturers combine the herbs because marketing narratives claim they act synergistically to support testosterone through separate biological mechanisms. Tongkat ali is promoted for reducing hormone binding and supporting luteinizing hormone, while Fadogia agrestis is marketed to mimic luteinizing hormone directly. However, no clinical trial has ever tested this combined botanical stack in humans. The combination pairs an herb with inconsistent human evidence alongside an unstudied botanical with documented rodent toxicity signals.
Is tongkat ali legal in the EU?
Tongkat ali cannot be lawfully sold as a food supplement across the European Union. In October 2021, the European Food Safety Authority assessed Eurycoma longifolia root extract as a novel food and concluded that its safety had not been established under any condition of use. Regulators rejected the application due to genotoxicity concerns, specifically positive results in an in vitro chromosome aberration test and an in vivo comet assay in gastrointestinal tissues.
Do these supplements contain what the label says?
Independent laboratory testing reveals frequent quality and authenticity failures. An analysis of eight commercial tongkat ali products found that three contained no detectable active material, while authentic bottles showed an eightfold variation in eurycomanone content. Similar testing on 17 Fadogia agrestis products found that five completely lacked target phenolics, with the remaining brands exhibiting a ninefold spread in active compounds. Adulteration with heavy metals and undeclared pharmaceutical analogues has also been documented.
Does raising testosterone within the normal range do anything?
Modest hormonal increases in healthy individuals produce minimal functional effects. Controlled clinical investigations, such as the landmark Testosterone Trials in older men, demonstrated that normalizing testosterone levels yielded moderate improvements in sexual desire and mood, but produced no measurable benefit for physical endurance, vitality, or walking distance. In men with normal baseline testosterone, slight shifts within the standard reference range have never been shown to enhance muscle mass, cognitive function, or daily performance.